Sandoz, a Novartis division, is a global leader in generic and biosimilar medicines. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our portfolio of approximately 1000 high-quality molecules, covering all major therapeutic areas, accounted for 2021 sales of USD 9.6 billion. Sandoz products reach approximately 500 million patients annually. The broad portfolio is spearheaded by leading global positions in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the backbone of global healthcare systems.
GET INVOLVED AT THE
WORLD ANTI-MICROBIAL RESISTANCE CONGRESS